Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Ability to understand and willingness to sign a written informed consent document.
Aged at least 18 years old.
Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB~IV).
Patients with previously untreated, EGFRm-positive (exon 19 deletion or L858R) and MET overexpression (IHC 3+) .
There are mutations of ALK or ROS1.
Have symptomatic and neurologically unstable central nervous system (CNS) metastases or CNS disease that requires increased steroid doses for control.
Pregnant or nursing women.